logo
  

Crown Crafts Q4 Profit Rises - Quick Facts

Crown Crafts Inc. (CRWS) said that its net income for the fourth quarter of fiscal 2014 increased to $2.0 million or $0.21 per share, from $1.9 million or $0.19 per share in the fourth quarter of fiscal 2013. Analysts polled by Thomson Reuters expected the company to report earnings of $0.22 per share for the quarter. Analysts' estimates typically exclude special items.

Quarterly net sales grew to $24.0 million from $23.6 million in the prior year.

The company stated that its steadily improving performance reflected the continued strength of its business strategy. Operationally, it was committed to continuous improvement and controlling costs wherever it can. Its financial position was strong, and it remained debt-free.

"On the heels of a strong prior year, we once again improved our performance as both net income and net sales increased in fiscal year 2014, even though we continue to operate in a challenging retail environment," said Randall Chestnut, Chairman, President and Chief Executive Officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT